LHF-535

Research use only, not for human use.

LHF-535 (LHF535, LHF 535) is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein, exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses with IC50 of 0.1-0.3 nM.

LHF-535 (LHF535, LHF 535) is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein, exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses with IC50 of 0.1-0.3 nM; LHF-535 has sub-nanomolar potency against the viral envelope glycoproteins from all Lassa virus lineages, with the exception of the glycoprotein from the LP strain from lineage I, which was 100-fold less sensitive than that of other strains; potently inhibited Junín virus, but not Candid#1 in virus-yield reduction assays; protects mice in a lethal Tacaribe virus model at 10 mg/kg.Other Indication Phase 1 Clinical.

——

Animal Model:IFN-α/β and-γ receptor-deficient AG129 mice Dosage:3, 10, or 30 mg/kg/day Administration:Orally; daily; 14 days Result:Effective as a post-exposure therapeutic.

LHF535 | LHF 535

Microbiology/Virology

Arenavirus

Arenavirus

Other Indications

Other Disease

1450929-77-7

412.533

C27H28N2O2

>98% (HPLC)

DMSO : 96.67 mg/mL 234.34 mM; H2O : < 0.1 mg/mL

CC(O)(C1=CC=C(/C=C\C2=CC=C3N(C4=CC=C(OC(C)C)C=C4)C=NC3=C2)C=C1)C

(Z)-2-(4-(2-(1-(4-isopropoxyphenyl)-1H-benzo[d]imidazol-5-yl)vinyl)phenyl)propan-2-ol

(-20℃)

With Ice Pack

≥ 2 years